Wanbury Past Earnings Performance
Past criteria checks 2/6
Wanbury has been growing earnings at an average annual rate of 18.5%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 9.6% per year.
Key information
18.5%
Earnings growth rate
14.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 9.6% |
| Return on equity | n/a |
| Net Margin | 4.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Wanbury makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 5,692 | 233 | 933 | 0 |
| 30 Sep 23 | 5,495 | 98 | 879 | 0 |
| 30 Jun 23 | 5,290 | 15 | 806 | 0 |
| 31 Mar 23 | 4,996 | -104 | 869 | 0 |
| 31 Dec 22 | 5,011 | 711 | 865 | 0 |
| 30 Sep 22 | 5,001 | 748 | 868 | 0 |
| 30 Jun 22 | 5,003 | 751 | 778 | 0 |
| 31 Mar 22 | 5,112 | 815 | 831 | 0 |
| 31 Dec 21 | 4,972 | -100 | 766 | 0 |
| 30 Sep 21 | 4,821 | -45 | 729 | 0 |
| 30 Jun 21 | 4,532 | -23 | 708 | 0 |
| 31 Mar 21 | 3,925 | -126 | 692 | 0 |
| 31 Dec 20 | 3,391 | 587 | 756 | 0 |
| 30 Sep 20 | 3,264 | 507 | 767 | 0 |
| 30 Jun 20 | 3,406 | 541 | 774 | 0 |
| 31 Mar 20 | 3,675 | 645 | 795 | 0 |
| 31 Dec 19 | 4,020 | -78 | 867 | 0 |
| 30 Sep 19 | 4,099 | -79 | 893 | 0 |
| 30 Jun 19 | 3,997 | -171 | 738 | 0 |
| 31 Mar 19 | 3,914 | -248 | 937 | 0 |
| 31 Mar 18 | 3,711 | -320 | 1,068 | 0 |
| 31 Mar 17 | 4,338 | 620 | 1,114 | 0 |
| 31 Mar 16 | 4,233 | -71 | 1,087 | 0 |
| 31 Mar 15 | 4,998 | 64 | 943 | 0 |
| 30 Sep 14 | 4,412 | -851 | 1,493 | 0 |
Quality Earnings: 524212 has high quality earnings.
Growing Profit Margin: 524212's current net profit margins (4.1%) are lower than last year (14.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524212 has become profitable over the past 5 years, growing earnings by 18.5% per year.
Accelerating Growth: 524212's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 524212 had negative earnings growth (-67.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (23.1%).
Return on Equity
High ROE: 524212's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.